Literature DB >> 29602894

Apixaban-induced subdural bleeding: case presentation and literature review.

Eman Alayad1, Sami Khairy2, Ahmed Aloraidi2.   

Abstract

Apixaban is a factor Xa inhibitor which is a non-vitamin K dependent oral anticoagulant known tocause the lowest rate of intracranial bleeding among the same kind of inibitors. In this paper, we report a rare case in a 60-year-old man with a history of hypertension and oligodendroglioma on apixaban for deep venous thrombosis who presented to our hospital with decreased level of consciousness and slurred speech with rapid deterioration. We highlight the risk of subdural bleeding requiring immediate neurosurgical intervention due to apixaban, with literature review. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drugs: cns (not psychiatric); neurological injury

Mesh:

Substances:

Year:  2018        PMID: 29602894      PMCID: PMC5884272          DOI: 10.1136/bcr-2018-224495

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Managing Nonoperable Intracranial Bleeding Associated With Apixaban: A Series of 2 Cases.

Authors:  Andrew C Faust; Dang M Tran; Catherine Lo; Sophia Lai; Lyndsay Sheperd; Mary Liu; Tina Denetclaw
Journal:  J Pharm Pract       Date:  2017-03-14

2.  Factor Eight Inhibitor Bypassing Agent (FEIBA) for Reversal of Target-Specific Oral Anticoagulants in Life-Threatening Intracranial Bleeding.

Authors:  Gordon Mao; Lauren King; Sarah Young; Richard Kaplan
Journal:  J Emerg Med       Date:  2016-12-19       Impact factor: 1.484

3.  Fatal consequences of climbing a ladder under apixaban and drunken.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Neurol Neurochir Pol       Date:  2016-02-05       Impact factor: 1.621

4.  [Apixaban-Related Convexal Subarachnoid Hemorrhage:A Case Report].

Authors:  Kiyoharu Shimizu; Kiyoshi Yuki; Takashi Sadatomo; Takeshi Hara; Hideo Ohba; Kaoru Kurisu
Journal:  No Shinkei Geka       Date:  2016-03

5.  Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity.

Authors:  Derrick R Rinehart; Nicholas R Lockhart; Leslie A Hamilton; J Russell Langdon; A Shaun Rowe
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

Review 6.  A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.

Authors:  Lahoud Touma; Kristian B Filion; Renée Atallah; Maria Eberg; Mark J Eisenberg
Journal:  Am J Cardiol       Date:  2014-12-02       Impact factor: 2.778

7.  Emergency neurosurgical care in patients treated with apixaban: report of 2 cases.

Authors:  Christopher Beynon; Anna Potzy; Andreas W Unterberg; Oliver W Sakowitz
Journal:  Am J Emerg Med       Date:  2014-12-18       Impact factor: 2.469

8.  Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.

Authors:  Betsy Karli; Billie Bartel; Rachel Pavelko
Journal:  Hosp Pharm       Date:  2015-07-31

9.  Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

Authors:  Koen M van Nieuwenhuizen; H Bart van der Worp; Ale Algra; L Jaap Kappelle; Gabriel J E Rinkel; Isabelle C van Gelder; Roger E G Schutgens; Catharina J M Klijn
Journal:  Trials       Date:  2015-09-04       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.